You are currently logged into
Cancer Health Directory - My Account or Log Out
Cancer Health Cancer Health
  • Home
  • News
    • News
    • Newsfeed
    • Science News
    • Features
    • Opinions
    • Conferences
    • Slideshows
    • Cancer Health TV
    • By Author
    • RSS Links
  • Cancer Basics
    • Cancer 101
    • Newly Diagnosed
    • Living with Cancer
    • Cancer Treatment
    • Cancer Medications
    • Breast Cancer
    • Colon Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
    • More Types of Cancer
    • Resources
  • Hot Topics
    • Coronavirus (COVID-19)
    • Health Equity
    • Cancer Treatment
    • Car-T Therapy
    • Caregivers
    • Chemotherapy
    • Immunotherapy
    • Marijuana
    • Mental Health
    • Quality of Life
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • Cancer Health Focus
    • Bulk Subscriptions
    • Email Newsletters
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Cancer Health Stories
    • Cancer Health Forums
    • Ask Cancer Health
    • Polls
    • Surveys
    • Quizzes
    • Calendar
    • Volunteer Jobs
    • Bookstore
    • Amazon Store
  • About Us
    • About Us
    • Masthead
    • Advertise
    • Awards
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#Kadcyla

Tweet
  • Share

Top 10 Cancer Treatment Highlights of 2019

FDA Approves Enhertu for HER2-Positive Advanced Breast Cancer

60% of women treated with the antibody-drug conjugate experienced complete or partial tumor shrinkage.

3D rendering of the breast

Tucatinib Fights Breast Cancer That Spreads to the Brain

New targeted therapy improves survival in people with metastatic HER2-positive breast cancer.

Hope Rugo, MD

Margetuximab May Offer New Option for Metastatic Breast Cancer

The novel immune-enhancing antibody delays disease progression, especially in people with a common genetic variant.

Kadcyla

FDA Approves Kadcyla for HER2-Positive Early Breast Cancer

Antibody-drug combination reduced the risk of recurrence after surgery by half compared with Herceptin.

Preventing Breast Cancer Recurrence

Kadcyla reduces the risk of breast cancer recurring and spreading after surgery.

Charles Geyer, Jr., MD

Kadcyla Reduces Breast Cancer Recurrence After Surgery

Experts say Kadcyla should become a new standard of care for adjuvant therapy.

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.